Trials of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, are documenting its direct kidney effects and broad benefits for diabetic kidney disease.
SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T ...
Keenova Therapeutics plc announced today that a new presentation on hepatorenal syndrome-acute kidney injury (HRS‑AKI) and TERLIVAZ® (terlipressin) will be shared at the Society of Hospital Medicine ...
An eGFR of 30 classifies her as stage 4 CKD, with advanced renal disease. Her sCr alone would not accurately depict the severity of her kidney disease because of her dietary intake and lack of muscle ...
THE WOODLANDS, Texas, March 24, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced three presentations of sotagliflozin clinical data during the American College of ...
THE UPSTATE NEEDS YOUR HELP WITH A NEW TEST STUDY. THE OBJECTIVE IS TO HELP A SPECIFIC GROUP OF PEOPLE IMPROVE THEIR CARDIOVASCULAR AND HEART FUNCTIONS. RASHAD WILLIAMS JOINS US IN STUDIO WITH MORE ON ...
Spread the loveVivoryon Therapeutics N.V. (Nasdaq: VVY) has made a significant stride in the treatment of diabetic kidney disease (DKD) by presenting an update on the role of glutaminyl cyclases as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results